AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL

Atherosclerosis

Volumn 192, Issue 2, 2007, Pages 298-304

  Isoda, Kikuo ^a   Folco, Eduardo J ^a   Shimizu, Koichi ^a   Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Cholesterol; Diabetes mellitus; Lipoprotein; Metabolism

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; BOVINE SERUM ALBUMIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; GLYCATION; HUMAN; HUMAN CELL; MACROPHAGE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; DNA-BINDING PROTEINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; SERUM ALBUMIN, BOVINE;

EID: 34248156708     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.023     Document Type: Article

References (42)

1. National diabetes fact sheet: general information and national estimates on diabetes in the United States ReA, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2004.
2. Basta G., Lazzerini G., Massaro M., et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
3. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37 (1998) 586-600
4. Schmidt A.M., Hasu M., Popov D., et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci USA 91 (1994) 8807-8811
5. Wautier J.L., Zoukourian C., Chappey O., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97 1 (1996) 238-243
6. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
7. Burke A.P., Kolodgie F.D., Zieske A., et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol 24 (2004) 1266-1271
8. Yan S.D., Schmidt A.M., Anderson G.M., et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269 (1994) 9889-9897
9. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
10. Schmidt A.M., Hori O., Chen J.X., et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 96 3 (1995) 1395-1403
11. Miyata T., Hori O., Zhang J., et al. The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 98 (1996) 1088-1094
12. Bierhaus A., Illmer T., Kasper M., et al. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96 (1997) 2262-2271
13. Valencia J.V., Mone M., Zhang J., et al. Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 53 (2004) 743-751
14. Valencia J.V., Mone M., Koehne C., Rediske J., and Hughes T.E. Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia 47 (2004) 844-852
15. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diab Care 21 (1998) 160-178
16. Stampfer M.J., Sacks F.M., Salvini S., Willett W.C., and Hennekens C.H. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 325 (1991) 373-381
17. Li A.C., and Glass C.K. The macrophage foam cell as a target for therapeutic intervention. Nat Med 8 (2002) 1235-1242
18. Brewer Jr. H.B., and Santamarina-Fojo S. Clinical significance of high-density lipoproteins and the development of atherosclerosis: focus on the role of the adenosine triphosphate-binding cassette protein A1 transporter. Am J Cardiol 92 (2003) 10K-16K
19. Fitzgerald M.L., Moore K.J., and Freeman M.W. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home. J Mol Med 80 5 (2002) 271-281
20. Wang N., Lan D., Chen W., Matsuura F., and Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101 (2004) 9774-9779
21. Kennedy M.A., Barrera G.C., Nakamura K., et al. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab 1 (2005) 121-131
22. Gelissen I.C., Harris M., Rye K.A., et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 26 (2006) 534-540
23. Valencia J.V., Weldon S.C., Quinn D., et al. Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal Biochem 324 (2004) 68-78
24. Schonbeck U., Mach F., Sukhova G.K., et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 189 (1999) 843-853
25. Beigneux A.P., Moser A.H., Shigenaga J.K., Grunfeld C., and Feingold K.R. The acute phase response is associated with retinoid X receptor repression in rodent liver. J Biol Chem 275 (2000) 16390-16399
26. Wellington C.L., Walker E.K., Suarez A., et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab Invest 82 (2002) 273-283
27. Klucken J., Buchler C., Orso E., et al. ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci USA 97 (2000) 817-822
28. Yamagishi S., Takeuchi M., Inagaki Y., Nakamura K., and Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 23 (2003) 129-134
29. Decottignies A., and Goffeau A. Complete inventory of the yeast ABC proteins. Nat Genet 15 (1997) 137-145
30. Schwiebert E.M. ABC transporter-facilitated ATP conductive transport. Am J Physiol 276 (1999) C1-C8
31. Porsch-Ozcurumez M., Langmann T., Heimerl S., et al. The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux. J Biol Chem 276 (2001) 12427-12433
32. Venkateswaran A., Repa J.J., Lobaccaro J.M., et al. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem 275 (2000) 14700-14707
33. Costet P., Luo Y., Wang N., and Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J Biol Chem 275 (2000) 28240-28245
34. Kaplan R., Gan X., Menke J.G., Wright S.D., and Cai T.Q. Bacterial lipopolysaccharide induces expression of ABCA1 but not ABCG1 via an LXR-independent pathway. J Lipid Res 43 (2002) 952-959
35. Lorkowski S., Rust S., Engel T., et al. Genomic sequence and structure of the human ABCG1 (ABC8) gene. Biochem Biophys Res Commun 280 (2001) 121-131
36. Martinez L.O., Agerholm-Larsen B., Wang N., Chen W., and Tall A.R. Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I. J Biol Chem 278 (2003) 37368-37374
37. Miller M., Rhyne J., Hamlette S., Birnbaum J., and Rodriguez A. Genetics of HDL regulation in humans. Curr Opin Lipidol 14 (2003) 273-279
38. Hong S.H., Rhyne J., and Miller M. Novel polypyrimidine variation (IVS46: del T -39 ... -46) in ABCA1 causes exon skipping and contributes to HDL cholesterol deficiency in a family with premature coronary disease. Circ Res 93 (2003) 1006-1012
39. Tan J.H., Low P.S., Tan Y.S., et al. ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore. Hum Genet 113 (2003) 106-117
40. Wang N., Silver D.L., Costet R., and Tall A.R. Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem 275 (2000) 33053-33058
41. Daimon M., Kido T., Baba M., et al. Association of the ABCA1 gene polymorphisms with type 2 DM in a Japanese population. Biochem Biophys Res Commun 329 (2005) 205-210
42. Vlassara H., Brownlee M., Manogue K.R., Dinarello C.A., and Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240 (1988) 1546-1548